Identification of serum angiopoietin-2 as a biomarker for clinical outcome of colorectal cancer patients treated with bevacizumab-containing therapy

2010186 citationsJournal Articlehybrid Open Access

Authors

Valentin Goede

Oliver Coutelle · University Hospital Cologne

Janina Neuneier · University Hospital Cologne

A. Reinacher-Schick · Bochum University of Applied Sciences

Rainer Schnell · Corner House

Thomas C. Koslowsky · Elisabeth-TweeSteden Ziekenhuis

Martin R. Weihrauch · University Hospital Cologne

Abstract

Serum Ang-2 is a candidate biomarker for outcome of patients with metastatic CRC treated with bevacizumab-containing therapy, and it should be further validated to customise combined chemotherapeutic and anti-angiogenic treatment.

Topics & Keywords

Colorectal Cancer Treatments and Studies Colorectal Cancer Surgical Treatments Angiogenesis and VEGF in Cancer

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: British Journal of Cancer

Volume 103, Issue 9, pp. 1407-1414

DOI: 10.1038/sj.bjc.6605925

Field-Weighted Citation Impact: 5.00